Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $11.13 to $11.30
• 50-Day Range: $9.80 to $15.83
• 52-Week Range: $9.68 to $17.31
• Volume: 4,335 shs
• Average Volume: 133,933 shs
• Market Capitalization: $273.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.25
• Consensus Rating: Buy

ARTV Stock Analysis - Frequently Asked Questions

How have ARTV shares performed this year?

Artiva Biotherapeutics' stock was trading at $11.77 at the beginning of 2024. Since then, ARTV stock has decreased by 5.4% and is now trading at $11.13.
View the best growth stocks for 2024 here.

How were Artiva Biotherapeutics' earnings last quarter?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.24.

When did Artiva Biotherapeutics IPO?

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share.

When does Artiva Biotherapeutics' lock-up period expire?

Artiva Biotherapeutics' lock-up period expires on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Who are Artiva Biotherapeutics' major shareholders?

Artiva Biotherapeutics' top institutional investors include RA Capital Management L.P. (40.57%), Geode Capital Management LLC (1.27%), Samsara BioCapital LLC (1.20%) and Wellington Management Group LLP (0.80%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio.
View institutional ownership trends.

How do I buy shares of Artiva Biotherapeutics?

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Artiva Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CUSIP: N/A
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.25
• High Stock Price Target: $23.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +93.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.33
• Quick Ratio: 11.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.28 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 24,290,000
• Free Float: N/A
• Market Cap: $266.22 million
• Optionable: N/A
• Beta: N/A